AU4320689A - Expression of retrovirus gag protein in eukaryotic cells - Google Patents

Expression of retrovirus gag protein in eukaryotic cells

Info

Publication number
AU4320689A
AU4320689A AU43206/89A AU4320689A AU4320689A AU 4320689 A AU4320689 A AU 4320689A AU 43206/89 A AU43206/89 A AU 43206/89A AU 4320689 A AU4320689 A AU 4320689A AU 4320689 A AU4320689 A AU 4320689A
Authority
AU
Australia
Prior art keywords
expression
eukaryotic cells
gag protein
retrovirus gag
retrovirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU43206/89A
Inventor
Dirk Gheysen
Eric Jacobs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of AU4320689A publication Critical patent/AU4320689A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
AU43206/89A 1988-06-03 1989-07-11 Expression of retrovirus gag protein in eukaryotic cells Abandoned AU4320689A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20227188A 1988-06-03 1988-06-03
US202271 1988-06-03

Publications (1)

Publication Number Publication Date
AU4320689A true AU4320689A (en) 1991-02-06

Family

ID=22749175

Family Applications (2)

Application Number Title Priority Date Filing Date
AU37256/89A Ceased AU627465B2 (en) 1988-06-03 1989-06-30 Expression of retrovirus gag protein in eukaryotic cells
AU43206/89A Abandoned AU4320689A (en) 1988-06-03 1989-07-11 Expression of retrovirus gag protein in eukaryotic cells

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU37256/89A Ceased AU627465B2 (en) 1988-06-03 1989-06-30 Expression of retrovirus gag protein in eukaryotic cells

Country Status (8)

Country Link
EP (1) EP0345242A3 (en)
AP (1) AP129A (en)
AU (2) AU627465B2 (en)
IL (1) IL90381A0 (en)
NZ (1) NZ229297A (en)
PT (1) PT90731A (en)
WO (1) WO1991000904A1 (en)
ZA (1) ZA894137B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU630649B2 (en) * 1988-12-01 1992-11-05 Smithkline Beecham Corporation Expression of hiv proteins in drosophila cells

Families Citing this family (257)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
US5786464C1 (en) * 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6290969B1 (en) 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6592877B1 (en) 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6534312B1 (en) 1996-02-22 2003-03-18 Merck & Co., Inc. Vaccines comprising synthetic genes
EP1997900A3 (en) 1996-04-05 2010-10-06 Novartis Vaccines and Diagnostics, Inc. Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
JP2001500738A (en) 1996-09-17 2001-01-23 カイロン コーポレイション Compositions and methods for treating intracellular diseases
US6114148C1 (en) * 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
EP0969862B1 (en) * 1997-02-07 2006-10-18 Merck & Co., Inc. Synthetic hiv gag genes
US6696291B2 (en) 1997-02-07 2004-02-24 Merck & Co., Inc. Synthetic HIV gag genes
US6261562B1 (en) 1997-02-25 2001-07-17 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
AU8692598A (en) 1997-08-04 1999-02-22 Calydon, Inc. A human glandular kallikrein enhancer, vectors comprising the enhancer and methods of use thereof
ATE476508T1 (en) 1997-11-06 2010-08-15 Novartis Vaccines & Diagnostic NEISSERIAL ANTIGENS
US6914131B1 (en) 1998-10-09 2005-07-05 Chiron S.R.L. Neisserial antigens
WO1999033869A2 (en) 1997-12-24 1999-07-08 Corixa Corporation Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
WO1999036544A2 (en) 1998-01-14 1999-07-22 Chiron S.P.A. Neisseria meningitidis antigens
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
EP1792988A3 (en) 1998-03-18 2007-08-22 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
EP2261349A3 (en) 1998-05-01 2012-01-11 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
WO2000008051A2 (en) 1998-08-07 2000-02-17 University Of Washington Immunological herpes simplex virus antigens and methods for use thereof
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
EP1121437B1 (en) 1998-10-15 2008-02-20 Novartis Vaccines and Diagnostics, Inc. Metastatic breast and colon cancer regulated genes
BR9916020A (en) 1998-12-08 2002-01-22 Corixa Corp Compounds and methods for the treatment and diagnosis of chlamydia infection
ES2310055T3 (en) 1998-12-16 2008-12-16 Novartis Vaccines & Diagnostic CYCLIN DEPENDENT HUMAN KINASE (HPNQALRE).
US20020119158A1 (en) 1998-12-17 2002-08-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6579973B1 (en) 1998-12-28 2003-06-17 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
US6602705B1 (en) 1998-12-31 2003-08-05 Chiron Corporation Expression of HIV polypeptides and production of virus-like particles
US7393823B1 (en) 1999-01-20 2008-07-01 Oregon Health And Science University HER-2 binding antagonists
US7625859B1 (en) 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
JP2002543769A (en) 1999-04-02 2002-12-24 コリクサ コーポレイション Compounds and methods for treatment and diagnosis of lung cancer
US8143386B2 (en) 1999-04-07 2012-03-27 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
WO2000066741A2 (en) 1999-04-30 2000-11-09 Chiron S.P.A. Conserved neisserial antigens
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
WO2001024820A1 (en) 1999-10-07 2001-04-12 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
ES2541830T3 (en) 1999-10-29 2015-07-27 Novartis Vaccines And Diagnositics S.R.L. Neisseria antigenic peptides
EP1232264B1 (en) 1999-11-18 2009-10-21 Novartis Vaccines and Diagnostics, Inc. Human fgf-21 gene and gene expression products
EP2275129A3 (en) 2000-01-17 2013-11-06 Novartis Vaccines and Diagnostics S.r.l. Outer membrane vesicle (OMV) vaccine comprising N. meningitidis serogroup B outer membrane proteins
EP1854476A3 (en) 2000-02-09 2008-05-07 Bas Medical, Inc. Use of relaxin to treat diseases related to vasoconstriction
DK1265915T3 (en) 2000-02-23 2011-02-14 Glaxosmithkline Biolog Sa New connections
AU2001241738A1 (en) 2000-02-25 2001-09-03 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
ES2281409T3 (en) 2000-02-28 2007-10-01 Novartis Vaccines And Diagnostics S.R.L. NEISSERIA PROTEIN HETEROLOGY EXPRESSION.
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
EP2075255A1 (en) 2000-03-08 2009-07-01 Novartis Vaccines and Diagnostics, Inc. Human FGF-23 gene and gene expression products
ES2303525T3 (en) 2000-04-21 2008-08-16 Corixa Corporation COMPOUNDS AND METHODS FOR THE TREATMENT AND DIAGNOSIS OF INFECTION BY CHLAMYDIA.
PT1284740E (en) 2000-05-19 2008-07-09 Corixa Corp Prophylactic and therapeutic treatment of infectious, autoimmune and allergic diseases with monosaccharide-based compounds
EP1950297A2 (en) 2000-05-31 2008-07-30 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers
US7700359B2 (en) 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
ES2305087T3 (en) 2000-06-15 2008-11-01 Novartis Vaccines And Diagnostics, Inc. POLINUCLEOTIDOS RELATED TO CANCER DE COLON.
ES2374620T3 (en) 2000-06-20 2012-02-20 Corixa Corporation ANTIGEN MTB32A OF MYCOBACTERIUM TUBERCULOSIS WITH THE ACTIVE ACTIVE SITE AND FUSION PROTEINS OF THEMSELVES.
EP1961819A3 (en) 2000-06-28 2008-11-12 Corixa Corporation Composition and methods for the therapy and diagnosis of lung cancer
US7691821B2 (en) 2001-09-19 2010-04-06 University Of South Florida Inhibition of SHIP to enhance stem cell harvest and transplantation
US20020165192A1 (en) 2000-09-19 2002-11-07 Kerr William G. Control of NK cell function and survival by modulation of ship activity
CA2425303A1 (en) 2000-10-27 2002-05-02 John Telford Nucleic acids and proteins from streptococcus groups a & b
CA2430379A1 (en) 2000-12-07 2002-06-13 Chiron Corporation Endogenous retroviruses up-regulated in prostate cancer
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
AU2002303261A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
WO2002081642A2 (en) 2001-04-06 2002-10-17 Georgetown University Gene brcc-3 and diagnostic and therapeutic uses thereof
AU2002305151A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene scc-112 and diagnostic and therapeutic uses thereof
EP1515982A4 (en) 2001-05-09 2005-10-26 Corixa Corp Compositions and methods for the therapy and diagnosis of prostate cancer
US20030198621A1 (en) 2001-07-05 2003-10-23 Megede Jan Zur Polynucleotides encoding antigenic HIV type B and/or type C polypeptides, polypeptides and uses thereof
CA2452015C (en) 2001-07-05 2012-07-03 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
EP1487854B1 (en) 2001-11-09 2010-04-28 Georgetown University Novel isoform of vascular endothelial cell growth inhibitor (vegi)
NZ546711A (en) 2001-12-12 2008-06-30 Chiron Srl Immunisation against chlamydia trachomatis
ES2405405T3 (en) 2001-12-17 2013-05-31 Corixa Corporation Compositions and procedures for the therapy and diagnosis of inflammatory bowel disease
CA2472282A1 (en) 2002-01-08 2003-07-17 Chiron Corporation Gene products differentially expressed in cancerous breast cells and their methods of use
AU2003213118A1 (en) 2002-02-15 2003-09-09 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
KR100981471B1 (en) 2002-03-15 2010-09-10 더 큐레이터스 오브 더 유니버시티 오브 미주리 Mutants of the p4 protein of nontypable haemophilus influenzae with reduced enzymatic activity
JP2005520543A (en) 2002-03-21 2005-07-14 サイグレス ディスカバリー， インコーポレイテッド Novel compositions and methods in cancer
US7244565B2 (en) 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
US7138512B2 (en) 2002-04-10 2006-11-21 Georgetown University Gene SHINC-2 and diagnostic and therapeutic uses thereof
US20030206916A1 (en) 2002-05-03 2003-11-06 Rush-Presbyterian-St. Luke's Medical Center Immunogenic peptides
CA2489292A1 (en) 2002-06-13 2003-12-24 Chiron Corporation Vectors for expression of hml-2 polypeptides
EP2316479B8 (en) 2002-07-18 2015-03-18 University of Washington Pharmaceutical compositions comprising immunologically active herpes simplex virus (HSV) protein fragments
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
SI1575517T1 (en) 2002-12-24 2012-06-29 Rinat Neuroscience Corp Anti-ngf antibodies and methods using same
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
EP1589934B1 (en) 2003-01-06 2015-09-23 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
US20040170982A1 (en) 2003-02-14 2004-09-02 Morris David W. Novel therapeutic targets in cancer
US7767387B2 (en) 2003-06-13 2010-08-03 Sagres Discovery, Inc. Therapeutic targets in cancer
US20070149449A1 (en) 2003-02-14 2007-06-28 Morris David W Therapeutic targets in cancer
PL379983A1 (en) 2003-02-19 2006-11-27 Rinat Neuroscience Corp. Methods for treating pain by administering a nerve growth factor antagonist and an nsaid and compositions containing the same
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
US8052966B2 (en) 2003-04-21 2011-11-08 University Of Southern California Methods and compositions for treating metastatic cancer
US20070178066A1 (en) 2003-04-21 2007-08-02 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
US7812116B2 (en) 2003-07-03 2010-10-12 Rush University Medical Center Immunogenic peptides
US7807646B1 (en) 2003-11-20 2010-10-05 University Of South Florida SHIP-deficiency to increase megakaryocyte progenitor production
US7763592B1 (en) 2003-11-20 2010-07-27 University Of South Florida SHIP-deficiency to increase megakaryocyte progenitor production
KR20070001932A (en) 2003-12-23 2007-01-04 리나트 뉴로사이언스 코퍼레이션 Agonist anti-trkc antibodies and methods using same
CN104292321A (en) 2004-03-29 2015-01-21 株式会社嘉尔药物 Novel modified galectin 9 protein and use thereof
JP5301152B2 (en) 2004-04-07 2013-09-25 ライナット ニューロサイエンス コーポレイション Method for treating bone cancer pain by administering a nerve growth factor antagonist
EP2848942B1 (en) 2004-07-14 2017-03-08 The Regents of The University of California Biomarkers for early detection of ovarian cancer
US20060024677A1 (en) 2004-07-20 2006-02-02 Morris David W Novel therapeutic targets in cancer
TWI355389B (en) 2004-07-30 2012-01-01 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide a
AU2005272920B2 (en) 2004-08-10 2011-05-12 Institute For Multiple Myeloma And Bone Cancer Research Methods of regulating differentiation and treating of multiple myeloma
ES2540770T3 (en) 2004-09-22 2015-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition for use in staphylococcal vaccination
JP2008530245A (en) 2005-02-18 2008-08-07 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド Antigens from uropathogenic strains
EP1701165A1 (en) 2005-03-07 2006-09-13 Johannes Dr. Coy Therapeutic and diagnostic uses of TKTL1 and inhibitors and activators thereof
WO2006104890A2 (en) 2005-03-31 2006-10-05 Glaxosmithkline Biologicals Sa Vaccines against chlamydial infection
WO2006110599A2 (en) 2005-04-07 2006-10-19 Novartis Vaccines And Diagnostics Inc. Cacna1e in cancer diagnosis, detection and treatment
JP2008535494A (en) 2005-04-07 2008-09-04 サグレシュ ディスカバリー， インコーポレイテッド Cancer-related gene (PRLR)
UY29504A1 (en) 2005-04-29 2006-10-31 Rinat Neuroscience Corp DIRECTED ANTIBODIES AGAINST BETA AMYLOID PEPTIDE AND METHODS USING THE SAME.
ES2524570T3 (en) 2005-04-29 2014-12-10 Glaxosmithkline Biologicals S.A. Procedure for prevention or treatment of infection with M. tuberculosis
KR20080039929A (en) 2005-07-22 2008-05-07 와이스 테라퓨틱스 가부시키가이샤 Anti-cd26 antibodies and methods of use thereof
DK3045182T3 (en) 2005-11-14 2018-03-19 Teva Pharmaceuticals Int Gmbh ANTAGONIST ANTIBODIES AGAINST CALCITONIN GEN-RELATED PEPTIDE TO TREAT HEAT
EP1979488A4 (en) 2006-01-09 2009-05-27 Univ California Immunostimulatory combinations of tnfrsf, tlr, nlr, rhr, purinergic receptor, and cytokine receptor agoinsts for vaccines and tumor immunotherapy
EP1981905B1 (en) 2006-01-16 2016-08-31 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Chlamydia vaccine
JP2009525319A (en) 2006-02-02 2009-07-09 ライナット ニューロサイエンス コーポレイション Method of treating obesity by administering a trkB antagonist
JP5524610B2 (en) 2006-04-07 2014-06-18 ザ リサーチ ファウンデーション オブ ステイト ユニバーシティー オブ ニューヨーク Transcobalamin receptor polypeptides, nucleic acids and modulators thereof, and related methods used to regulate cell growth and to treat cancer and cobalamin deficiency
CN103709252B (en) 2006-06-07 2016-12-07 生物联合公司 Identify antibody and the using method thereof of the sugary epi-position of CD-43 and CEA expressed on cancerous cell
US20100015168A1 (en) 2006-06-09 2010-01-21 Novartis Ag Immunogenic compositions for streptococcus agalactiae
US20100166788A1 (en) 2006-08-16 2010-07-01 Novartis Vaccines And Diagnostics Immunogens from uropathogenic escherichia coli
EP2139447A2 (en) 2007-03-20 2010-01-06 Harold Brem Gm-csf cosmeceutical compositions and methods of use thereof
EP2170384B1 (en) 2007-07-02 2016-04-13 Etubics Corporation Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
JP5737944B2 (en) 2007-12-17 2015-06-17 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ Treatment of interstitial cystitis
SG186669A1 (en) 2007-12-18 2013-01-30 Bioalliance Cv Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
EP2274437B1 (en) 2008-04-10 2015-12-23 Cell Signaling Technology, Inc. Compositions and methods for detecting egfr mutations in cancer
WO2009150623A1 (en) 2008-06-13 2009-12-17 Pfizer Inc Treatment of chronic prostatitis
TWI516501B (en) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Pcsk9 antagonists
US20110287026A1 (en) 2008-09-23 2011-11-24 President And Fellows Of Harvard College Sirt4 and uses thereof
US9181315B2 (en) 2009-01-08 2015-11-10 Dana-Farber Cancer Institute, Inc. Compositions and methods for induced brown fat differentiation
WO2010086828A2 (en) 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Agonist anti-trkb monoclonal antibodies
AU2010220103A1 (en) 2009-03-06 2011-09-22 Novartis Ag Chlamydia antigens
WO2010118243A2 (en) 2009-04-08 2010-10-14 Genentech, Inc. Use of il-27 antagonists to treat lupus
SG175092A1 (en) 2009-04-14 2011-11-28 Novartis Ag Compositions for immunising against staphylococcus aerus
WO2010146511A1 (en) 2009-06-17 2010-12-23 Pfizer Limited Treatment of overactive bladder
ES2526996T3 (en) 2009-07-16 2015-01-19 Novartis Ag Detoxified immunogens from Escherichia coli
US8563261B2 (en) 2009-09-28 2013-10-22 The Trustees Of The University Of Pennsylvania Method of diagnosing and treating interstitial cystitis
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
CA2787628A1 (en) 2010-01-21 2011-07-28 Dana-Farber Cancer Institute, Inc. Context specific genetic screen platform to aid in gene discovery and target validation
PT2528621T (en) 2010-01-27 2016-12-20 Glaxosmithkline Biologicals Sa Modified tuberculosis antigens
US8298535B2 (en) 2010-02-24 2012-10-30 Rinat Neuroscience Corp. Anti-IL-7 receptor antibodies
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
PE20130393A1 (en) 2010-03-11 2013-04-07 Rinat Neuroscience Corp ANTIBODIES WITH PH-DEPENDENT ANTIGEN UNION
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
WO2011133931A1 (en) 2010-04-22 2011-10-27 Genentech, Inc. Use of il-27 antagonists for treating inflammatory bowel disease
US8747844B2 (en) 2010-07-30 2014-06-10 Saint Louis University Methods of treating pain
US9539427B2 (en) 2010-11-08 2017-01-10 The Johns Hopkins University Methods for improving heart function
EP2663868A2 (en) 2010-12-01 2013-11-20 The University of North Carolina at Chapel Hill Methods and compositions for targeting sites of neovascular growth
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
WO2012154994A2 (en) 2011-05-10 2012-11-15 The Regents Of The University Of Californa A novel adenovirus isolated from titi monkeys
US10221218B2 (en) 2011-05-10 2019-03-05 The Regents Of The University Of California Adenovirus isolated from titi monkeys
WO2012177595A1 (en) 2011-06-21 2012-12-27 Oncofactor Corporation Compositions and methods for the therapy and diagnosis of cancer
US20130071375A1 (en) 2011-08-22 2013-03-21 Saint Louis University Compositions and methods for treating inflammation
WO2013028527A1 (en) 2011-08-23 2013-02-28 Indiana University Research And Technology Corporation Compositions and methods for treating cancer
US9241976B2 (en) 2011-08-29 2016-01-26 The Regents Of The University Of California Use of HDL-related molecules to treat and prevent proinflammatory conditions
CA2848368C (en) 2011-09-13 2023-02-14 Dana-Farber Cancer Institute, Inc. Compositions and methods for brown fat induction and activity using fndc5
WO2013055911A1 (en) 2011-10-14 2013-04-18 Dana-Farber Cancer Institute, Inc. Znf365/zfp365 biomarker predictive of anti-cancer response
SG11201401699WA (en) 2011-11-11 2014-09-26 Rinat Neuroscience Corp Antibodies specific for trop-2 and their uses
WO2013093693A1 (en) 2011-12-22 2013-06-27 Rinat Neuroscience Corp. Staphylococcus aureus specific antibodies and uses thereof
EP2794659A1 (en) 2011-12-22 2014-10-29 Rinat Neuroscience Corp. Human growth hormone receptor antagonist antibodies and methods of use thereof
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
WO2014031178A1 (en) 2012-08-24 2014-02-27 Etubics Corporation Replication defective adenovirus vector in vaccination
AU2013343099A1 (en) 2012-11-09 2015-05-14 Pfizer Inc. Platelet-derived growth factor B specific antibodies and compositions and uses thereof
CN105246337B (en) 2013-03-14 2019-02-15 吉恩维沃公司 Thymidine kinase diagnostic analysis for gene therapy application
US9428537B2 (en) 2013-03-15 2016-08-30 The Board Of Trustees Of The Leland Stanford Junior University tRNA derived small RNAs (tsRNAs) involved in cell viability
CN105051068A (en) 2013-03-15 2015-11-11 戴埃克斯有限公司 Anti-plasma kallikrein antibodies
KR102267292B1 (en) 2013-03-15 2021-06-21 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Mitochondrial-derived peptide mots3 regulated metabolism and cell survival
CA2909721A1 (en) 2013-04-19 2014-10-23 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Lone star virus
RU2015147721A (en) 2013-05-07 2017-06-15 Ринат Нейросаенз Корпорэйшн ANTIBODIES AGAINST GLUCAGON RECEPTOR AND METHODS OF USING THEM
WO2014210546A1 (en) 2013-06-27 2014-12-31 University Of Washington Through Its Center For Commercialization Biocompatible polymeric system for targeted treatment of thrombotic and hemostatic disorders
CA2953917C (en) 2013-07-01 2021-10-19 The Research Foundation For The State University Of New York Ship inhibition to combat obesity
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
AR097102A1 (en) 2013-08-02 2016-02-17 Pfizer ANTI-CXCR4 ANTIBODY AND ANTIBODY AND DRUG CONJUGATES
WO2015073580A1 (en) 2013-11-13 2015-05-21 Pfizer Inc. Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof
WO2015087187A1 (en) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anti-sclerostin antibodies
WO2015109212A1 (en) 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
PE20161439A1 (en) 2014-03-21 2017-01-26 Teva Pharmaceuticals Int Gmbh ANTIBODIES ANTAGONISTS DIRECTED AGAINST THE PEPTIDE RELATED TO THE CALCITONIN GENE AND METHODS USING THE SAME
US11624093B2 (en) 2014-04-24 2023-04-11 Dana-Farber Cancer Institute, Inc. Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
US10308697B2 (en) 2014-04-30 2019-06-04 President And Fellows Of Harvard College Fusion proteins for treating cancer and related methods
ES2913205T3 (en) 2014-05-13 2022-06-01 Bioatla Inc Conditionally active biological proteins
AU2015280433B2 (en) 2014-06-17 2020-10-08 The Research Foundation For The State University Of New York Ship inhibition to induce expression of granulocyte colony stimulating factor in a subject
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
AU2015308818B2 (en) 2014-08-28 2021-02-25 Bioatla Llc Conditionally active chimeric antigen receptors for modified T-cells
JP2017532019A (en) 2014-09-03 2017-11-02 バイオアトラ、エルエルシー Discovery and production of conditionally active biological proteins in the same eukaryotic cell production host
SG10201902168PA (en) 2014-09-09 2019-04-29 Unum Therapeutics Chimeric receptors and uses thereof in immune therapy
AU2015328411C1 (en) 2014-10-06 2022-03-03 Dana-Farber Cancer Institute, Inc. Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
AU2015328163B2 (en) 2014-10-09 2020-10-15 Dana-Farber Cancer Institute, Inc. Multiple-variable IL-2 dose regimen for treating immune disorders
TWI595006B (en) 2014-12-09 2017-08-11 禮納特神經系統科學公司 Anti-pd-1 antibodies and methods of use thereof
CA2977532A1 (en) 2015-03-06 2016-09-15 Dana-Farber Cancer Institute, Inc. Pd-l2 biomarkers predictive of pd-1 pathway inhibitor responses in esophagogastric cancers
EP3270897A4 (en) 2015-03-20 2018-12-05 The Regents Of The University Of Michigan Immunogenic compositions for use in vaccination against bordetella
US9758575B2 (en) 2015-04-06 2017-09-12 Yung Shin Pharmaceutical Industrial Co. Ltd. Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof
TWI787645B (en) 2015-04-13 2022-12-21 美商輝瑞股份有限公司 Cd3-specific antibodies, therapeutic bispecific antibodies and their uses
WO2017015334A1 (en) 2015-07-21 2017-01-26 Saint Louis University Compositions and methods for diagnosing and treating endometriosis-related infertility
CN108137705B (en) 2015-07-21 2022-11-08 武田药品工业株式会社 Monoclonal antibody inhibitor of factor XIIA
WO2017015619A1 (en) 2015-07-23 2017-01-26 The Regents Of The University Of California Antibodies to coagulation factor xia and uses thereof
IL302353A (en) 2015-08-19 2023-06-01 Pfizer Tissue factor pathway inhibitor antibodies and uses thereof
EP3350220B1 (en) 2015-09-15 2021-05-19 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
WO2017062246A1 (en) 2015-10-05 2017-04-13 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human rota virus g9p[6] strain and use as a vaccine
EP3362472B1 (en) 2015-10-16 2023-08-30 The Trustees of Columbia University in the City of New York Compositions and methods for inhibition of lineage specific antigens
US11207393B2 (en) 2015-10-16 2021-12-28 President And Fellows Of Harvard College Regulatory T cell PD-1 modulation for regulating T cell effector immune responses
US10138298B2 (en) 2015-10-23 2018-11-27 The Regents Of The University Of California Anti-IL-2 antibodies and compositions and uses thereof
WO2017075037A1 (en) 2015-10-27 2017-05-04 Scholar Rock, Inc. Primed growth factors and uses thereof
US20210106661A1 (en) 2015-10-29 2021-04-15 Dana-Farber Cancer Institute, Inc. Methods for identification, assessment, prevention, and treatment of metabolic disorders using pm20d1 and n-lipidated amino acids
CN106699889A (en) 2015-11-18 2017-05-24 礼进生物医药科技（上海）有限公司 PD-1 resisting antibody and treatment application thereof
RU2744860C2 (en) 2015-12-30 2021-03-16 Кодиак Сайенсиз Инк. Antibodies and their conjugates
ES2904593T3 (en) 2016-01-21 2022-04-05 Pfizer Monospecific and bispecific antibodies to epidermal growth factor receptor variant III and CD3 and their uses
US20210309965A1 (en) 2016-03-21 2021-10-07 Dana-Farber Cancer Institute, Inc. T-cell exhaustion state-specific gene expression regulators and uses thereof
JP7099967B2 (en) 2016-07-01 2022-07-12 リサーチ ディベロップメント ファウンデーション Elimination of Proliferative Cells from Stem Cell-Derived Grafts
US11136409B2 (en) 2016-09-20 2021-10-05 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of AML using USP10 biomarkers and modulators
US20180119141A1 (en) 2016-10-28 2018-05-03 Massachusetts Institute Of Technology Crispr/cas global regulator screening platform
WO2018148246A1 (en) 2017-02-07 2018-08-16 Massachusetts Institute Of Technology Methods and compositions for rna-guided genetic circuits
US11198735B2 (en) 2017-03-03 2021-12-14 Rinat Neuroscience Corp. Anti-GITR antibodies and methods of use thereof
US20200056190A1 (en) 2017-03-16 2020-02-20 Pfizer Inc. Tyrosine prototrophy
CA3059938A1 (en) 2017-04-14 2018-10-18 Kodiak Sciences Inc. Complement factor d antagonist antibodies and conjugates thereof
CA3006798A1 (en) 2017-06-02 2018-12-02 Pfizer Inc. Antibodies specific for flt3 and their uses
GB2576680B (en) 2017-06-13 2022-03-23 Bostongene Corp Systems and methods for generating, visualizing and classifying molecular functional profiles
BR112020000679A2 (en) 2017-07-13 2020-07-14 Massachusetts Institute Of Technology targeting the hdac2-sp3 complex to enhance synaptic function
WO2019016784A1 (en) 2017-07-21 2019-01-24 Universidade De Coimbra Anti-nucleolin antibody
EP3661555A4 (en) 2017-08-01 2021-07-14 Ab Studio Inc. Bispecific antibodies and uses thereof
EP3692370A2 (en) 2017-10-04 2020-08-12 OPKO Pharmaceuticals, LLC Articles and methods directed to personalized therapy of cancer
SG11202003443TA (en) 2017-11-24 2020-05-28 Eucure Beijing Biopharma Co Ltd Anti-ox40 antibodies and uses thereof
AU2019215075A1 (en) 2018-02-01 2020-08-20 Pfizer Inc. Antibodies specific for CD70 and their uses
SG11202006883QA (en) 2018-02-01 2020-08-28 Pfizer Chimeric antigen receptors targeting cd70
EP3755342A4 (en) 2018-02-21 2021-11-24 The University Of Montana Diaryl trehalose compounds and uses thereof
EP3755716A4 (en) 2018-02-23 2021-08-04 Eucure (Beijing) Biopharma Co., Ltd Anti-pd-1 antibodies and uses thereof
KR20200128116A (en) 2018-02-28 2020-11-11 화이자 인코포레이티드 IL-15 variants and uses thereof
US11572381B2 (en) 2018-03-02 2023-02-07 The University Of Montana Immunogenic trehalose compounds and uses thereof
CA3100829A1 (en) 2018-05-23 2019-11-28 Pfizer Inc. Antibodies specific for gucy2c and uses thereof
EP3797121A1 (en) 2018-05-23 2021-03-31 Pfizer Inc Antibodies specific for cd3 and uses thereof
SG11202100510PA (en) 2018-07-20 2021-02-25 Eucure Beijing Biopharma Co Ltd Anti-cd40 antibodies and uses thereof
BR112021003670A2 (en) 2018-08-28 2021-05-18 Vor Biopharma, Inc. genetically modified hematopoietic stem cells and their uses
BR112021004698A2 (en) 2018-09-12 2021-06-01 Eucure (Beijing) Biopharma Co., Ltd anti-tnfrsf9 antibodies and their uses
CN113227142B (en) 2018-11-19 2022-11-29 百奥赛图(北京)医药科技股份有限公司 anti-PD-1 antibodies and uses thereof
SG11202112870WA (en) 2019-05-23 2021-12-30 The Univ Of Montana Vaccine adjuvants based on tlr receptor ligands
US20210005283A1 (en) 2019-07-03 2021-01-07 Bostongene Corporation Techniques for bias correction in sequence data
US20240050529A1 (en) 2019-10-07 2024-02-15 University Of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
EP4041773A1 (en) 2019-10-11 2022-08-17 Beth Israel Deaconess Medical Center, Inc. Anti-tn antibodies and uses thereof
US20230067811A1 (en) 2020-01-24 2023-03-02 University Of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
WO2021205325A1 (en) 2020-04-08 2021-10-14 Pfizer Inc. Anti-gucy2c antibodies and uses thereof
WO2021224850A1 (en) 2020-05-06 2021-11-11 Crispr Therapeutics Ag Mask peptides and masked anti-ptk7 antibodies comprising such
JP2023533793A (en) 2020-07-17 2023-08-04 ファイザー・インク Therapeutic antibodies and their uses
CA3190227A1 (en) 2020-07-30 2022-02-03 Pfizer Inc. Cells having gene duplications and uses thereof
EP4343004A2 (en) 2020-10-19 2024-03-27 Dana-Farber Cancer Institute, Inc. Germline biomarkers of clinical response and benefit to immune checkpoint inhibitor therapy
WO2022104104A2 (en) 2020-11-13 2022-05-19 Dana-Farber Cancer Institute, Inc. Personalized fusion cell vaccines
US20240029829A1 (en) 2020-12-04 2024-01-25 Bostongene Corporation Hierarchical machine learning techniques for identifying molecular categories from expression data
WO2022159793A2 (en) 2021-01-25 2022-07-28 Dana-Farber Cancer Institute, Inc. Methods and compositions for identifying neuroendocrine prostate cancer
US20220372580A1 (en) 2021-04-29 2022-11-24 Bostongene Corporation Machine learning techniques for estimating tumor cell expression in complex tumor tissue
WO2022261183A2 (en) 2021-06-08 2022-12-15 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
WO2023012627A1 (en) 2021-08-02 2023-02-09 Pfizer Inc. Improved expression vectors and uses thereof
WO2023049933A1 (en) 2021-09-27 2023-03-30 Sotio Biotech Inc. Chimeric receptor polypeptides in combination with trans metabolism molecules that re-direct glucose metabolites out of the glycolysis pathway and therapeutic uses thereof
WO2023091909A1 (en) 2021-11-16 2023-05-25 Sotio Biotech Inc. Treatment of myxoid/round cell liposarcoma patients
WO2023097119A2 (en) 2021-11-29 2023-06-01 Dana-Farber Cancer Institute, Inc. Methods and compositions to modulate riok2
US20230245479A1 (en) 2022-01-31 2023-08-03 Bostongene Corporation Machine learning techniques for cytometry
WO2023148598A1 (en) 2022-02-02 2023-08-10 Pfizer Inc. Cysteine prototrophy
WO2023158732A1 (en) 2022-02-16 2023-08-24 Dana-Farber Cancer Institute, Inc. Methods for decreasing pathologic alpha-synuclein using agents that modulate fndc5 or biologically active fragments thereof
WO2024015561A1 (en) 2022-07-15 2024-01-18 Bostongene Corporation Techniques for detecting homologous recombination deficiency (hrd)
WO2024040207A1 (en) 2022-08-19 2024-02-22 Sotio Biotech Inc. Genetically engineered natural killer (nk) cells with chimeric receptor polypeptides in combination with trans metabolism molecules and therapeutic uses thereof
WO2024040208A1 (en) 2022-08-19 2024-02-22 Sotio Biotech Inc. Genetically engineered immune cells with chimeric receptor polypeptides in combination with multiple trans metabolism molecules and therapeutic uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5931799A (en) * 1982-08-16 1984-02-20 Science & Tech Agency Recombinant plasmid and preparation of transformed yeast and hepatitis virus b surface antigen using the same
US4703008A (en) * 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
NZ217645A (en) * 1985-09-25 1991-11-26 Oncogen Recombinant viruses expressing lav/htlv-iii related epitopes and vaccine formulations
EP0230222A1 (en) * 1986-01-06 1987-07-29 F. Hoffmann-La Roche Ag Expression of HTLV-III gag-Gene
AU1391888A (en) * 1987-02-11 1988-09-14 Scripps Clinic And Research Foundation Retroviral expression vectors and methods for producing hbv antigens
IL90048A0 (en) * 1988-04-25 1989-12-15 Merck & Co Inc Recombinant gag precursor of hiv,its preparation and its use as aids vaccine

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU630649B2 (en) * 1988-12-01 1992-11-05 Smithkline Beecham Corporation Expression of hiv proteins in drosophila cells

Also Published As

Publication number Publication date
AU627465B2 (en) 1992-08-27
NZ229297A (en) 1992-01-29
EP0345242A2 (en) 1989-12-06
ZA894137B (en) 1990-06-27
AP129A (en) 1991-04-17
AP8900126A0 (en) 1989-07-31
IL90381A0 (en) 1989-12-15
PT90731A (en) 1989-12-29
EP0345242A3 (en) 1990-05-30
WO1991000904A1 (en) 1991-01-24
AU3725689A (en) 1991-01-03

Similar Documents

Publication Publication Date Title
AU3725689A (en) Expression of retrovirus gag protein in eukaryotic cells
AU4403689A (en) Hiv proteins and peptides useful in the diagnosis, prophylaxis or therapy of aids
AU3069189A (en) Retroviral packaging cell lines and processes of using same
AU599091B2 (en) Expression and purification of an htlv-iii gag/env gene protein
AU585180B2 (en) Nor-statine and nor-cyclostatine polypeptides
AU7184487A (en) Human g-csf protein expression
GB8817997D0 (en) Enzyme electrodes & improvements in manufacture thereof
AU4636589A (en) Tissue culture antiviral processes and compositions
AU2783989A (en) Immortalized human cell lines
AU3745589A (en) Peptides having t cell helper activity
AU3114489A (en) Hammermill
AU6399786A (en) Polypeptides used in the diagnosis and therapy of AIDS
AU3170089A (en) Mutated hiv envelope protein
AU2614888A (en) Soluble human cd4 fragments and uses therefor
NZ224667A (en) Stable human cell lines expressing foreign gene under hiv ltr regulatory control
AU7270387A (en) Enhanced expression of human interleukin-2 in mammalian cells
AU2157888A (en) Novel hiv proteins and peptides useful in the diagnosis, prophylaxis or therapy of aids
AU3006789A (en) Expression of hiv binding proteins
AU4257789A (en) Electro-insertion of proteins into animal cell membranes
AU2818289A (en) Electrochemical cells
AU8891691A (en) Human proteins having anticoagulant and anti-inflammatory activity
AU3836489A (en) Treatment of immunodeficiency
AU2579688A (en) Expression of hiv proteins in e. coli and s. cerevisiae
AU3625589A (en) Htlv-i / hiv-1 fusion proteins
IE891750L (en) Expression of retrovirus gag protein in eukaryotic cells